Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2014 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Sigma-Tau S.p.A. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Sigma-Tau S.p.A. - Product Pipeline Review - 2014', provides an overview of the Sigma-Tau S.p.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Sigma-Tau S.p.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Sigma-Tau S.p.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Sigma-Tau S.p.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Sigma-Tau S.p.A.'s pipeline products Reasons to buy - Evaluate Sigma-Tau S.p.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Sigma-Tau S.p.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Sigma-Tau S.p.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Sigma-Tau S.p.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sigma-Tau S.p.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Sigma-Tau S.p.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Sigma-Tau S.p.A. Snapshot 6 Sigma-Tau S.p.A. Overview 6 Key Information 6 Key Facts 6 Sigma-Tau S.p.A. - Research and Development Overview 7 Key Therapeutic Areas 7 Sigma-Tau S.p.A. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Sigma-Tau S.p.A. - Pipeline Products Glance 15 Sigma-Tau S.p.A. - Late Stage Pipeline Products 15 Pre-Registration Products/Combination Treatment Modalities 15 Phase III Products/Combination Treatment Modalities 16 Sigma-Tau S.p.A. - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Sigma-Tau S.p.A. - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Sigma-Tau S.p.A. - Drug Profiles 20 (simvastatin + omega 3 fatty acids) 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 acetyl-L-carnitine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 procarbazine hydrochloride 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Avidin 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 levocarnitine propionate hydrochloride 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 (dihydroartemisinin + piperaquine) 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 AvidinOx 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 namitecan 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 SST-0001 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ST-4206 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 DN-30 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 PTX3 Protein 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ST-4070 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 tenatumomab 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Sigma-Tau S.p.A. - Pipeline Analysis 36 Sigma-Tau S.p.A. - Pipeline Products by Target 36 Sigma-Tau S.p.A. - Pipeline Products by Route of Administration 37 Sigma-Tau S.p.A. - Pipeline Products by Molecule Type 38 Sigma-Tau S.p.A. - Pipeline Products by Mechanism of Action 39 Sigma-Tau S.p.A. - Recent Pipeline Updates 40 Sigma-Tau S.p.A. - Dormant Projects 41 Sigma-Tau S.p.A. - Company Statement 42 Sigma-Tau S.p.A. - Locations And Subsidiaries 43 Head Office 43 Other Locations & Subsidiaries 43 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables Sigma-Tau S.p.A., Key Information 6 Sigma-Tau S.p.A., Key Facts 6 Sigma-Tau S.p.A. - Pipeline by Indication, 2014 9 Sigma-Tau S.p.A. - Pipeline by Stage of Development, 2014 10 Sigma-Tau S.p.A. - Monotherapy Products in Pipeline, 2014 11 Sigma-Tau S.p.A. - Combination Treatment Modalities in Pipeline, 2014 12 Sigma-Tau S.p.A. - Out-Licensed Products in Pipeline, 2014 13 Sigma-Tau S.p.A. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 Sigma-Tau S.p.A. - Pre-Registration, 2014 15 Sigma-Tau S.p.A. - Phase III, 2014 16 Sigma-Tau S.p.A. - Phase II, 2014 17 Sigma-Tau S.p.A. - Phase I, 2014 18 Sigma-Tau S.p.A. - Preclinical, 2014 19 Sigma-Tau S.p.A. - Pipeline by Target, 2014 36 Sigma-Tau S.p.A. - Pipeline by Route of Administration, 2014 37 Sigma-Tau S.p.A. - Pipeline by Molecule Type, 2014 38 Sigma-Tau S.p.A. - Pipeline Products by Mechanism of Action, 2014 39 Sigma-Tau S.p.A. - Recent Pipeline Updates, 2014 40 Sigma-Tau S.p.A. - Dormant Developmental Projects,2014 41 Sigma-Tau S.p.A., Subsidiaries 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
